Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
NCT05981235
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
OTHER
Sponsor class
Conditions
Gastrointestinal Tumors
Interventions
BIOLOGICAL:
AZD6422 CLDN18.2 CAR-T product
Sponsor
Peking University
Collaborators
[object Object]